Suven Life Sciences Announces 37th AGM and FY26 Annual Report
Suven Life Sciences Ltd has announced its 37th Annual General Meeting (AGM) to be held on August 25, 2026, via Video Conference. The company also released its Annual Report for the Financial Year 2025-26. Key highlights from the report indicate insignificant revenue growth (₹21.05 Cr in FY26 vs ₹17.55 Cr in FY25), increased R&D investment (₹291.62 Cr in FY26 vs ₹172.43 Cr in FY25), and a widened net loss (₹276.34 Cr in FY26 vs ₹160.75 Cr in FY25). The report details the company's progress on its clinical-stage assets, including Masupirdine (Phase 3 for Alzheimer's), Samelisant (Phase 3 for EDS), and Ropanicant (Phase 2b completed for MDD). The company emphasizes its long-term strategy in CNS research, backed by a significant patent portfolio and a dedicated research team.
Key Highlights
- AGM scheduled for August 25, 2026, via Video Conference.
- FY26 saw revenue growth, increased R&D spend, and a wider net loss.
- Masupirdine and Samelisant are progressing in Phase 3 clinical trials.
- Company holds over 3,056 global patents for 62 inventions.
- Focus remains on long-term CNS drug development pipeline.
Price Impact
More from SUVEN